A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [PDF]
British Journal of Cancer, 2002 Pancreatic cancer is the fifth most common cause of cancer death in the western world and the prognosis for unresectable disease remains poor. Recent advances in conventional chemotherapy and the development of novel ‘molecular’ treatment strategies with
Simon R. Bramhall +5 more
openalex +2 more sources
Inpharma Weekly, 1999 An orally-active synthetic hydroxamate with potential antineoplastic activity. Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix ...
semanticscholar +4 more sources
Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling. [PDF]
Mol Cell ProteomicsSmith CF +15 more
europepmc +2 more sources
Incorporation of Bulky and Cationic Cyclam‐Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity [PDF]
ChemistryOpen, 2013 The synthesis and matrix metalloproteinase (MMP) inhibitory activity of a cyclam–marimastat conjugate and its metal complexes are described. The conjugate, synthesized with a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition (“click” reaction ...
Mingfeng Yu +6 more
openalex +2 more sources
Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA [PDF]
British Journal of Cancer, 1999 SummaryInhibition of matrix metalloproteinases (MMPs) is an attractive approach to adjuvant therapy in the treatment of cancer. Marimastat is the first orally administered, synthetic MMP inhibitor to be evaluated, in this capacity, in the clinic ...
Sue‐Ann Watson +5 more
openalex +2 more sources
Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers [PDF]
British Journal of Clinical Pharmacology, 1998 Andrew Millar +6 more
openalex +2 more sources
Journal of British Surgery, 1999 Abstract Background Abdominal aortic aneurysms are characterized by degradation of the extracellular matrix, with a reduction in the elastin concentration of the arterial media. These changes have been linked to increased levels of endogenous metalloproteinases (MMPs) within the aorta, particularly ...
G D, Treharne +5 more
openaire +3 more sources
Toxicon: X, 2022 Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming by Dispholidus typus (boomslang) results in venom-induced consumption coagulopathy (VICC), whereby highly abundant prothrombin-activating snake venom ...
Stefanie K. Menzies +11 more
doaj +1 more source
Toxins, 2022 Envenomation by elapid snakes primarily results in neurotoxic symptoms and, consequently, are the primary focus of therapeutic research concerning such venoms. However, mounting evidence suggests these venoms can additionally cause coagulopathic symptoms,
Arif Arrahman +7 more
doaj +1 more source
Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. [PDF]
PLoS ONE, 2010 Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however,
Vincent E de Meijer +7 more
doaj +1 more source